Decreased fibrinolytic activity in porcine-to-primate cardiac xenotransplantation

Molecular Medicine

Volumn 4, Issue 9, 1998, Pages 629-637

  Kalady, Matthew F ^a   Lawson, Jeffrey H ^a   Sorrell, Rachelle D ^a   Platt, Jeffrey L ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BABOON; COMPLEMENT ACTIVATION; CONTROLLED STUDY; FIBRINOLYSIS; HEART TRANSPLANTATION; IMMUNOCYTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; SWINE; VASCULAR ENDOTHELIUM; XENOTRANSPLANTATION;

EID: 0031753040     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03401762     Document Type: Article

References (44)

1. Platt JL, Vercellotti GM, Dalmasso AP, Matas AJ, Bolman RM, Najarian JS, Bach FH. (1990) Transplantation of discordant xenografts: a review of progress. Immunol. Today 11: 450-456.
2. Auchincloss H, Jr. (1998) Xenogeneic transplantation. Transplantation 46: 1-20.
3. Platt JL, Fischel RJ, Matas AJ, Reif SA, Bolman RM, Bach FH. (1991) Immunopathology of hyperacute xenograft rejection in a swine-to-primate model. Transplantation 52: 214-220.
4. Parker W, Saadi S, Lin SS, Holzknecht ZE, Bustos M, Platt JL. (1996) Transplantation of discordant xenografts: a challenge revisited. Immunol. Today 17: 373-378.
5. Cooper DKC, Human PA, Lexer G, Rose AG, Rees J, Keraan M, Du Toit E. (1988) Effects of cyclosporine and antibody adsorption on pig cardiac xenograft survival in the baboon. J. Heart Transplant 7: 238-246.
6. Leventhal JR, Dalmasso AP, Cromwell JW, Platt JL, Manivel CJ, Bolman RM, Matas AJ. (1993) Prolongation of cardiac xenograft survival by depletion of complement. Transplantation 55: 857-866.
7. Pruitt SK, Kirk AD, Bollinger RR, et al. (1994) The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation 57: 363-370.
8. McCurry KR, Kooyman DL, Alvarado CG, Cotterell AH, Martin MJ, Logan JS, Platt JL. (1995) Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nature Med. 1: 423-427.
9. Magee JC, Collins BH, Harland RC, Lindman BJ, Bollinger RR, Frank MM, Platt JL. (1995) Immunoglobulin prevents complement mediated hyperacute rejection in swine-to-primate xenotransplantation. J. Clin. Invest. 96: 2404-2412.
10. Lin SS, Kooyman DL, Daniels LJ, et al. (1997) The role of natural anti-Galα1-3Gal antibodies in hyperacute rejection of pig-to-baboon cardiac xenotransplants. Transplant Immunol. 5: 212-218.
11. Leventhal JR, Matas AJ, Sun LH, Reif S, Bolman RM, III, Dalmasso AP, Platt JL. (1993) The immunopathology of cardiac xenograft rejection in the guinea pig to rat model. Transplantation 56: 1-8.
12. Levin E, Loskutoff D. (1982) Cultured bovine endothelial cells produce both urokinase and tissue-type plasminogen activators. J. Cell Biol. 94: 631-639.
13. Kristensen P, Larsson L, Nielsen LS, Grondahl-Hansen J, Andreasen PA, Dano K. (1984) Human endothelial cells contain one type of plasminogen activator. FEBS Lett. 168: 33-37.
14. Collen D, Lijnen HR. (1991) Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 78: 3114-3124.
15. Schleef RF, Loskutoff DJ. (1988) Fibrinolytic system of vascular endothelial cells: role of plasminogen activator inhibitors. Haemostasis 18: 328-341.
16. Sprengers ED, Kluft C. (1987) Plasminogen activator inhibitors. Blood 69: 381-387.
17. Lijnen H, Collen D. (1997) Endothelium in hemostasis and thrombosis. Prog. Cardiovasc. Dis. 4: 343-350.
18. Rosenberg RD, Rosenberg JS. (1984) Natural anticoagulent mechanisms. J. Clin. Invest. 74: 1-6.
19. Wiman B, Ljungberg B, Chmielewska J, Urden G, Blomback M, Johnsson H. (1985) The role of the fibrinolytic system in deep vein thrombosis. J. Lab. Clin. Med. 105: 265-270.
20. Nilsson IM, Ljungner MH, Tengborn L. (1985) Two different mechanisms in patients with deep vein thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br. Med. J. 290: 1453-1455.
21. Hamsten A, Wilman B, deFaire U, Blomback M. (1985) Increased plasma levels of a rapid inhibitor to tissue plasminogen activator in young survivors of myocardial infarction. N. Engl. J. Med. 313: 1557-1563.
22. Aznar J, Estelles A, Torino G, Sapena P, Tormo V, Blanch S, Espana F. (1988) Plasminogen activator activity and other fibrinolytic variables in patients with coronary artery disease. Br. Heart J. 59: 535-541.
23. Labarrere CA, Pitts D, Nelson DR, Faulk WP. (1995) Vascular tissue plasminogen activator and the development of coronary artery disease in heart transplantation recipients. N. Engl. J. Med. 333: 1111-1116.
24. Booth N, Bennett B, Wijngaards G, Grieve JH. (1983) A new life-long hemorrhagic disorder due to excess plasminogen activator. Blood 61: 267-275.
25. Aznar J, Estelles A, Villa V, Reganon E, Espana F, Villa P. (1984) Inherited fibrinolytic disorder due to an enhanced plasminogen activator level. ThrombHaemostasis 52: 196-202.
26. (1995). Tissue plasminogen activator for acute ischemic stroke. National Institute of Neurological Disorders and rt-PA Stroke Study. N. Engl. J. Med. 333: 1587-1592.
27. Verstraete M. (1990) Thrombolytic treatment in acute myocardial infarction. Circulation 82(suppl): II96-109.
28. Yusuf S, Sleight P, Held P, McMahon S. (1990) Routine medical management of acute myocardial infarction: lessons from overviews of recent randomized controlled trials. Circulation 82(3 suppl): II117-134.
29. Byrne GW, McCurry KR, Martin MJ, McClellan SM, Platt JL, Logan JS. (1997) Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage. Transplantation 63: 149-155.
30. Lawson JH, Daniels LJ, Hoopes CW, et al. (1997) The role of transgenic expression of human complement regulatory proteins in discordant xenotransplantation. Proceedings for the 52nd Annual Sessions of the Owen H. Wangensteen Surgical Forum 1997 Clinical Congress, Vol. XLVIII. American College of Surgeons, Chicago, pp. 487-489.
31. Platt JL, LeBien TW, Michael AF. (1982) Interstitial mononuclear cell populations in renal graft rejection: identification by monoclonal antibodies in tissue sections. J. Exp. Med. 155: 17-30.
32. Soeda S, Kakiki M, Shimeno H, Nagamatsu A. (1986) Rapid and high-yield purification of porcine heart tissue-type plasminogen activator by heparin-sepharose chromatography. Life Sci. 39: 1317-1324.
33. Hanss M, Collen D. (1987) Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by cultured human endothelial cells: modulation by thrombin, endotoxin, and histamine. J. Lab. Clin. Med. 109: 97-104.
34. Lawson JH, Platt JL. (1996) Molecular barriers to xenotransplantation. Transplantation 62: 303-310.
35. Saadi S, Holzkhecht RA, Patte CP, Stern DM, PLatt JL. (1995) Complement-mediated regulation of tissue factor activity in endothelium. J. Exp. Med. 182: 1807-1814.
36. Fryer JP, Chen S, Johnson E, Simone P, Sun LH, Goswitz JJ, Matas AJ. (1997) The role of monocytes and macrophages in delayed xenograft rejection. Xenotransplantation 4: 40-48.
37. Platt JL, Vercellotti GM, Lindman BJ, Oegema TR, Jr, Bach FH, Dalmasso AP. (1990) Release of heparan sulfate from endothelial cells: implications for the pathogenesis of hyperacute rejection. J. Exp. Med. 171: 1363-1368.
38. Moore KL, Andreoli SP, Esmon NL, Esmon CT, Bang NU. (1987) Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J. Clin. Invest. 79: 124-130.
39. Lawson JH, Daniels L, Platt JL. (1997) The evaluation of thrombomodulin activity in porcine to human xenotransplantation. Transplant Proc. 29: 884-885.
40. Van Hinsberg VWM, Kooistra T, Emeis JJ, Koolwijk P. (1991) Regulation of plasminogen activator production by endothelial cells: role in fibrinolysis and local proteolysis. Int. J. Radiat. Biol. 60: 261-272.
41. Diamond S, Eskin S, McIntire L. (1989) Fluid flow stimulates tissue plasminogen activator secretion by cultured human endothelial cells. Science 243: 1483-1485.
42. Levin EG, Marzec U, Anderson J, Harker LA. (1984) Thrombin stimulates tissue plasminogen activator release from cultured human endothelial cells. J. Clin. Invest. 74: 1988-1995.
43. Schleef RR, Bevilacqua MP, Sawdey M, Gimbrone MA, Jr, Loskutoff DJ. (1988) Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J. Biol. Chem. 263: 5797-5803.
44. Emeis JJ, Kooistra T. (1986) Interleukin 1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J. Exp. Med. 163: 1260-1266.